Small interfering RNA-induced CHFR silencing sensitizes oral: Squamous cell cancer cells to microtubule inhibitors

Cancer Biology and Therapy

Volumn 4, Issue 7, 2005, Pages 773-780

  Ogi, Kazuhiro ^a   Toyota, Minoru ^a,b   Mita, Hiroaki ^a   Satoh, Ayumi ^a   Kashima, Lisa ^a   Sasaki, Yasushi ^a   Suzuki, Hiromu ^a   Akino, Kimishige ^a   Nishikawa, Noriko ^a   Noguchi, Makoto ^a   Shinomura, Yasuhisa ^a   Imai, Kohzoh ^a   Hiratsuka, Hiroyoshi ^a   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Checkpoint; Mitosis; Molecular target therapy

Indexed keywords

CYCLIN B1; DOCETAXEL; HISTONE H3; PACLITAXEL; SERINE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; METAPHASE; MOUTH CARCINOMA; PHOSPHORYLATION; PROPHASE; SQUAMOUS CELL CARCINOMA;

EID: 25144497990     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.7.1896     Document Type: Article

References (29)

1. Sudbo J, Reith A. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int J Cancer 2005; 115:339-45.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
3. Yao L, Iwai M, Furuta I. Correlations of bcl-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral Oncol 1999; 35:56-62.
4. Cortez D, Elledge SJ. Conducting the mitotic symphony. Nature 2000; 406:354-6.
5. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24:139-45.
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9.
7. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74.
8. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 2003; 23:5556-71.
9. Porter LA, Cukier IH, Lee JM. Nuclear localization of cyclin Bl regulates DNA damage-induced apoptosis. Blood 2003; 101:1928-33.
10. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and nonsmall cell lung cancer. Carcinogenesis 2003; 24:47-51.
11. Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnick DM, Kittas C, Halazonetis TD, Gorgoulis VG. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res 2003; 63:7185-9.
12. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, Takahashi T. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 2002; 21:2328-33.
13. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003; 63:8606-13.
14. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406:430-5.
15. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003; 100:7818-23.
16. 2 to M transition. J Cell Biol 2002; 156:249-59.
17. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J, Chen J. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005; 37:401-6.
18. Huang M, Elledge SJ. The FHA domain, a phosphoamino acid binding domain involved in the DNA damage response pathway. Cold Spring Harb Symp Quant Biol 2000; 65:413-21.
19. Durocher D, Henckel J, Fersht AR, Jackson SP. The FHA domain is a modular phosphopeptide recognition motif. Mol Cell 1999; 4:387-94.
20. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406:430-5.
21. Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 2002; 62:1797-801.
22. Trowbridge IS. Interspecies spleen-myeloma hybrid producing monoclonal antibodies against mouse lymphocyte surface glycoprotein, T200. J Exp Med 1978; 148:313-23.
23. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 2004; 40:1000-6.
24. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003; 116:3677-85.
25. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997; 57:1013-9.
26. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20:147-55.
27. Summers MK, Bothos J, Halazonetis TD. The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus. Oncogene 2005; 24:2589-98.
28. Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD. The Chfr mitotic checkpoint protein functions with Ubc1 3-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene 2003; 22:7101-7.
29. Heliez C, Baricault L, Barboule N, Valette A. Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 2003; 22:3260-8.